Who Exports Oxaliplatin from India — 249 Suppliers Behind a $46.6M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for pharmaceutical manufacturing and research. The city contributes approximately 40% of the country's bulk drug production, underscoring its significance in the pharmaceutical sector. The establishment of Genome Valley, a premier biotech cluster, has attracted over 200 life sciences companies, including global giants such as Novartis, Bayer, and Sanofi. This ecosystem fosters innovation and large-scale production, making Hyderabad a key player in the global pharmaceutical supply chain.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara serving as major pharmaceutical hubs. The region is home to several large pharmaceutical companies, including Sun Pharmaceuticals, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Alembic Pharmaceuticals, Intas Pharmaceuticals, and Zydus Lifesciences. These companies have established a strong presence in both domestic and international markets, contributing significantly to the pharmaceutical industry's growth.

The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, hosts numerous pharmaceutical companies with extensive export operations. The region's well-developed infrastructure, including major ports and international airports, facilitates efficient global distribution of pharmaceutical products. This strategic location enhances India's position in the global pharmaceutical market, ensuring timely delivery and compliance with international standards.

Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the region, contributing to its rapid industrial growth. The cluster's focus on cost-effective production has made it an attractive destination for pharmaceutical manufacturing, particularly for companies looking to optimize operational costs.

• Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.

• Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers, especially those involved in the production of Oxaliplatin, to ensure consistent quality and regulatory adherence.

• Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline global distribution and reduce lead times.

• Monitor Regulatory Changes: Stay informed about tax incentives and regulatory changes in regions like Baddi-Nalagarh to capitalize on cost-saving opportunities.

By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance supply chain resilience and ensure a steady supply of high-quality pharmaceuticals like Oxaliplatin.